血清NSE及其半衰期诊断与监测小细胞肺癌的评价

Evaluation of serum neuron-specific enolase and its half-life analysis in diagnosis and follow-up of small cell lung cancer

目的：评价小细胞肺癌（SCLC）患者血清神经元特异性烯醇化酶（NSE）在该病的诊断、化疗和复发中的意义以及NSE半衰期与SCLC复发的关系。方法：用双抗体夹心ELISA法测定NSE含量。结果：NSE诊断SCLC的敏感性、特异性及准确度分别为85．0％、85．3％、88．7％；其中局限期（LS）SCLC和广泛期（ES）SCLC患者的阳性率分别为71，4％、92．3％，NSE半衰期大于20d者，其复发在发病前为47～183d前即被发现，NSE的半衰期预测SCLC复发敏感性为80．0％。结论：血清NSE检测对SCLC与NSCLC的鉴别诊断具有重要意义，NSE半衰期预测SCLC复发的敏感性优于NSE含量测定。

Objective：To evaluate the clinical value of detection of serum neuron-specific enolase （S-NSE） level and its half-life in differential diagnosis monitoring of chemotherapy and prediction of relapse of small cell lung cancer （ SCLC ）. Methods： The double mAb sandwich ELISA was used. Results： The sensitivity, specificity, and accuracy of the ELISA tests for detection of serum NSE were 85.0%, 85.3%, 88.7% respectively. The positive rates of serum NSE detected in limited stage （LS） and extensive stage（ES） patients with SCLC were 71.4%, 92.3% ; The patients whose serum NSE half-life were more than 20ds, the relapse would found from 47-183d since they had been found to be SCLC, the sensitivity of prediction of relapse by half-life of NSE was 80.0%. Conclusion： Detection of serum NSE level is of significance in differentiation between SCLC and NSCLC. The half-Life of serum NSE predicting the relapse of SCLC is better than the detection of serum NSE.